All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

GSK's Nucala (mepolizumab) wins MHRA approval for eosinophilic chronic obstructive pulmonary disease following Ph3 trials
Antibody, respiratory, monoclonal antibody, COPD, IL-5 inhibitor, add-on therapy - Read more

GSK's Shingrix (recombinant zoster vaccine) prefilled syringe presentation wins European Commission approval for shingles prevention
Vaccine, infectious disease, recombinant vaccine, shingles, varicella zoster virus - Read more

FDA approves Octapharma USA's new 2-gram Fibryga (fibrinogen) presentation for acquired fibrinogen deficiency treatment
Protein therapy, hematological, fibrinogen concentrate, acquired fibrinogen deficiency, hemostasis, bleeding disorders - Read more

THE GOOD
Business Development & Partnerships

Eli Lilly, InduPro partner on cancer treatment discovery using AI platform, $950M potential deal value
Research collaboration, oncology, AI/ML, antibody, milestone payments - Read more

Basilea Pharmaceutica, Prokaryotics collaborate on broad-spectrum antifungal development, $48.5M milestones
Research collaboration, infectious disease, small molecule, milestone payments - Read more

Amgen, DISCO Pharmaceuticals partner on cancer surfaceome tech, potentially worth over $618 million
Licensing deal, oncology, drug discovery, antibody, milestone payments - Read more

Daiichi Sankyo, Genesis Pharma partner on Vanflyta commercialization across 13 European markets
Licensing deal, oncology, commercialization, small molecule - Read more

Lonza's Synaffix, Sidewinder Therapeutics partner on multi-target bispecific ADCs with milestones and royalties
Licensing deal, oncology, antibody-drug conjugates, milestone payments - Read more

RoslinCT, BOOST Pharma partner on manufacturing BT-101 cell therapy for osteogenesis imperfecta
Manufacturing agreement, rare disease, cell therapy, GMP manufacturing - Read more

Relation Therapeutics, Deerfield team up to build newcos around AI-identified drug targets
Research collaboration, AI/ML, drug discovery, joint venture - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

GSK's bepirovirsen shows potential as first finite six-month treatment for chronic hepatitis B
Antisense oligonucleotide, infectious disease, hepatitis B, functional cure, finite therapy - Read more

BridgeBio Oncology Therapeutics' BBO-8520 shows 65% response rate in KRAS G12C non-small cell lung cancer Ph1 trial
Small molecule, cancer, KRAS inhibitor, non-small cell lung cancer, pancreatic cancer, combination therapy - Read more

THE GOOD
Company Launches

Poplar Therapeutics launches with $50M Series A to advance PHB-050, a next-generation anti-IgE therapy for food allergy
Clinical-stage, immunology, antibody, food allergy, atopic diseases - Read more

THE GOOD
Fundraises

Soley Therapeutics raises $200M Series C, advancing oncology assets to clinic
Oncology, AI/ML platform, cellular stress sensing, preclinical, platform technology - Read more

Rakuten Medical raises $100M funding, light-based cancer therapy toward 2028 FDA filing
Cancer, photoimmunotherapy, antibody conjugates, clinical-stage - Read more

Corsera Health raises $80M Series A, preventative heart disease siRNA therapies
Cardiovascular, siRNA, preventative medicine, AI-enabled, clinical-stage - Read more

Mediar Therapeutics raises $76M Series B, advancing first-in-class fibrosis therapies
Fibrosis, clinical-stage, small molecule, systemic sclerosis, chronic kidney disease - Read more

Spiro Medical raises $67M Series A, neuromodulation system for asthma treatment
Neuromodulation, asthma, respiratory disease, medical device - Read more

STRM.BIO raises $8M Series Seed 2, non-viral gene therapy delivery platform
Gene therapy, non-viral delivery, platform technology, preclinical - Read more

Praxis Precision Medicines announces proposed public offering for CNS disorder therapies
Neurological, CNS disorders, clinical-stage, precision medicine - Read more

Monte Rosa Therapeutics raises $200M public offering, developing molecular glue degrader medicines
Clinical-stage, small molecule, molecular glue degrader, platform technology - Read more

THE GOOD
Investments

Celltrion opens first US manufacturing plant in New Jersey for $330M to stabilize supply chain
Biologics, strategic, major transaction, operational - Read more

THE GOOD
Market Reports

Eli Lilly's orforglipron and retatrutide dominate Clarivate's 2026 drugs to watch list with massive projections
GLP-1 receptor agonist, cardiometabolic, strategic, major transaction, competitive - Read more

THE GOOD
Mergers & Acquisitions

WEP Clinical acquires European CRO Siron Clinical to expand global capabilities in rare disease trials
Rare disease, pediatric, strategic, major transaction - Read more

Eli Lilly to acquire Ventyx Biosciences for $1.2B to expand oral immune drug pipeline
NLRP3 inhibitor, autoimmune, strategic, major transaction - Read more

THE GOOD
Product Launches

Bial launches new sublingual apomorphine treatment for Parkinson's OFF episodes in UK
Small molecule, neurological, strategic, operational - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Pulmocide terminates opelconazole Ph3 trial for treatment-resistant invasive pulmonary aspergillosis after interim analysis shows higher mortality
Small molecule, infectious disease, azole antifungal, invasive pulmonary aspergillosis, immunocompromised patients - Read more

Rezolute shares Ph3 sunRIZE insights for ersodetug in congenital hyperinsulinism, misses primary endpoints
Small molecule, metabolic, congenital hyperinsulinism, hypoglycemia, insulin receptor antagonist - Read more

THE BAD
Lawsuits

Bayer sues Moderna, Pfizer, BioNTech, J&J over alleged COVID vaccine patent infringement seeking royalties
mRNA vaccine, infectious disease, competitive, major transaction - Read more

THE BAD
Mergers & Acquisitions

AbbVie denies $20B acquisition talks with Revolution Medicines, sending cancer drugmaker's shares down 13%
Small molecule, oncology, strategic, major transaction - Read more

THE BAD
Regulatory

FDA criticizes Esperion Therapeutics' Nexlizet TV ad for misleading claims and distracting animated characters
Small molecule, cardiovascular, regulatory, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here